•In a retrospective HNSCC cohort, pre-treatment BCL2-positive tumors have shorter progression-free and overall survival and higher tumor recurrence rates when BCL2 status is analyzed by immunohistochemistry. The gene discussed is BCL2; the disease is neoplasm.